Recent studies recommend stratifying EC patients according to the percentage of ERα IHC-positive tumor cells into three groups: high-risk (<10%), intermediate-risk (20–80%), and low-risk (90–100%) groups [53,85]. Here, ESR1 is linked to neoplasm.